Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Q-Bot Fundraising

30 Jul 2024 07:00

RNS Number : 2950Y
NetScientific PLC
30 July 2024
 

RNS: 7.00 a.m. on 30 July 2024

 

NetScientific plc

 

(NetScientific, the Group or the Company)

 

Q-Bot Limited (Q-Bot) Fundraising

 

Issue of Shares and Total Voting Rights

 

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that portfolio company Q-Bot, a robotics-as-a-service construction tech company, has successfully closed a fundraising of £1.5 million (Fundraising).

Fundraising

The Fundraising was led and syndicated by EMV Capital, the Company's wholly owned venture capital and corporate finance firm, and includes a subscription for £1.25 million of new shares in the capital of Q-Bot and a loan facility of £250,000 (such loan facility amount being part of a re-financed loan of c.£785,000). It follows an initial fundraising earlier in 2024 of c.£1.4 million (also led and syndicated by EMV Capital) received from advance subscription agreements (ASAs) and a convertible loan agreement (CLA). The Fundraising will provide Q-Bot with working capital to progress its revised business plan, which includes rationalising its business into two separate divisions, an installations business and a technologies focused business. The planned restructuring allows the installations business to attract investment to reach break-even and accelerate growth, and the technologies business to operate on a standalone basis and exploit multiple existing and new US and EU growth opportunities to create further value.

The Group has participated directly in the Fundraising, including:

· a £349,968.22 subscription for Q-Bot shares, such amount to settled by the Company issuing to Q-Bot 411,727 new ordinary shares in the capital of the Company (Consideration Shares) at a price of £0.85 per New Share, a 35.0 per cent. premium to the closing price of the Company's ordinary shares on 29 July 2024; and

· a £198,143.92 advance subscription pursuant to an ASA, converting outstanding fees due to EMV Capital into Q-Bot shares.

EMV Capital's EMVC Evergreen EIS Fund has also participated in the ASA.

The Consideration Shares are subject to orderly market provisions such that if they are to be disposed of they must be sold through the Company's broker.

Following completion of the Fundraising, the total equity holding of the Group in Q-Bot is increased to 17.0 per cent, which equates to a post-investment fair value of £2.7 million, a decrease of 28.3 per cent. from the £3.8 million reported as at 31 December 2023. In addition, following the introduction of investors to Q-Bot by EMV Capital, the NetScientific third party assets under management with Q-Bot is 37.4 per cent. of the share capital, which equates to a post-investment fair value of £6.0 million, a decrease of 30.3 per cent. from the £8.6 million reported as at 31 December 2023. Such percentage holdings are based on issued share capital, and subject to dilution by the CLA and certain warrants and options.

Q-Bot is a well-known robotics and automation company in the growing Construction Tech and Climate Solutions area, with sales in the UK and Europe. Using AI and robotics, Q-Bot's insulation is deployed beneath suspended timber floors or to the underside of suspended concrete floors. A remotely operated robotic device applies a continuous layer of spray-foam insulation to the underside of the floor, resulting in a reduction in heat loss through the floor and a barrier to cold air draughts.

Q-Bot's advanced insulation has generated £11.6 million in revenues from nearly 5,000 installations in the UK (including through partners) and over £200,000 in revenues from installations in France. 

Following the Fundraising, Malcolm Groat, currently a non-executive investor director of Q-Bot, will become Chair of Q-Bot.

Dr Ilian Iliev, CEO of NetScientific and Investment Director of Q-Bot, commented:

"We are pleased to see Q-Bot close this fundraising. The company's technology licensing, and installations business units each have a route to break-even within this vast market, and we wish it every success in executing on its plans to grow the technology platform, including on an international scale, whilst servicing a high-quality existing UK sales pipeline."

Admission of Consideration Shares and Total Voting Rights

Application will be made for the Consideration Shares, which will rank pari passu with existing Ordinary Shares, to be admitted to AIM (Admission). It is expected that Admission will become effective and dealings will commence at 8.00 a.m. on or around 2 August 2024.

Following Admission, the total issued share capital of the Company will consist of 24,357,555 Ordinary Shares. The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company will be 24,357,555 Ordinary Shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The person responsible for arranging the release of this announcement on behalf of the Company is Edward Hooper, General Counsel and Executive Director of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

Panmure Liberum Limited (NOMAD and Broker)

 

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

Belvedere Communications

John West / Llewellyn Angus / Lily Pearce

 

+44 (0)20 7653 8702

 

About NetScientific

NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally.

The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-efficient investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net www.netscientific.net  

 

About Q-Bot

Q-Bot, founded in 2012 by Tom Lipinski and Professor Peter Childs FREng, is a provider to the UK Government's Green Homes Local Authority Delivery Scheme, the Social Housing Decarbonisation Fund, Great British Insulation Scheme and Home Upgrade Grant. 

Q-Bot's floor insulation is installed in over 200 homes every month and to date the company has installed nearly 5,000 properties across the UK and Europe. The company works with over 50 registered social housing providers, energy companies such as E.ON and British Gas, as well as a network of accredited installers and property agents.

An average-sized UK household, insulated by Q-Bot, could typically save c.£850 per year in an electrically-heated home, and c.£270 a year in a gas-heated home. Studies show that the Q-Bot system reduces heat loss through the floor by 77% and cold draughts by 1/3 for the whole house. With retrofitting existing buildings seen as essential for the UK to reach Net Zero, a household using Q-Bot's solution can cut its annual CO emissions by an average 700 kg.

Q-Bot's work has received grant support from the UK Government and Innovate UK, and it has won numerous awards, including the CIBSE Building Performance Award and the Queen's Award for Enterprise (Innovation). 

www.q-bot.co

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURFFFIFDFIAFIS
Date   Source Headline
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone
10th Nov 20211:58 pmRNSPDS Reports Q3 2021 Results & Business Update
4th Nov 20217:00 amRNSSofant Signs EUR7.3m ESA Contract
1st Nov 20212:16 pmRNSPDS to License Novel Proteins for Flu Vaccine
26th Oct 20217:00 amRNSEMV Capital Participates in £843k Sofant Funding
22nd Oct 202111:18 amRNSProAxsis announces the approval of a key US patent
22nd Oct 20219:04 amRNSHolding(s) in Company
21st Oct 20214:40 pmRNSSecond Price Monitoring Extn
21st Oct 20214:35 pmRNSPrice Monitoring Extension
21st Oct 20212:17 pmRNSPDS Phase 2 Clinical Trial Update
5th Oct 20217:00 amRNSPDS Phase 2 Clinical Trial Update
4th Oct 20217:00 amRNSInvestor Presentations
30th Sep 202110:22 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSGrant of Options to Directors
29th Sep 20217:00 amRNSInterim Results
20th Sep 20217:00 amRNSNotice of Results and Analyst Briefing
16th Sep 20217:00 amRNSInvestment in Martlet Capital Limited
9th Aug 20215:59 pmRNSHolding(s) in Company
30th Jul 20219:12 amRNSHolding(s) in Company
26th Jul 20214:25 pmRNSHolding(s) in Company
22nd Jul 20214:29 pmRNSHolding(s) in Company
20th Jul 20212:05 pmRNSSecond Price Monitoring Extn
20th Jul 20212:00 pmRNSPrice Monitoring Extension
16th Jul 202110:35 amRNSDirector/PDMR Shareholding
1st Jul 202112:08 pmRNSHolding(s) in Company
30th Jun 20213:42 pmRNSHolding(s) in Company
30th Jun 202110:29 amRNSHolding(s) in Company
30th Jun 202110:27 amRNSHolding(s) in Company
28th Jun 20213:18 pmRNSResult of General Meeting, TVR & PDMR Dealings
22nd Jun 20217:00 amRNSPDS Announces Closing of c. $52m Public Offering
16th Jun 20217:00 amRNSNSCI Participates in $45m PDS Equity Issue
15th Jun 20217:00 amRNSPDS announces proposed offering of common stock
10th Jun 202112:56 pmRNSResult of Placing and Total Voting Rights
10th Jun 20217:00 amRNSProposed Placing
9th Jun 20214:40 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.